A Novel Metabolic Liver Fibrosis Risk Score for the Identification of Elevated Liver Stiffness in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Study
By: Szymon Suwała, Paweł Rajewski and Roman Junik
References
- RAJEWSKI P, CIEŚCIŃSKI J, RAJEWSKI P, SUWAŁA S, RAJEWSKA A, POTASZ M. Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines 2025;13:217.
- TARGHER G, BYRNE CD, TILG H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024:gutjnl-2023-330595..
- PARSIAN H, ALIZADEH M, YAHYAPOUR Y. Clinical Application of Non-Invasive Markers of Liver Fibrosis. Practical Management of Chronic Viral Hepatitis, InTech; 2013
- RINELLA ME, LAZARUS J V., RATZIU V, FRANCQUE SM, SANYAL AJ, KANWAL F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966–86.
- (EASL) EA FOR THE S OF THE L, (EASD) EA FOR THE S OF D, (EASO) EA FOR THE S OF O. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts 2024;17:374–443.
- WU Y-L, KUMAR R, WANG M-F, SINGH M, HUANG J-F, ZHU Y-Y, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2021;27:5753–63.
- THEOFILIS P, VORDONI A, KALAITZIDIS RG. Metabolic Dysfunction-Associated Fatty Liver Disease in the National Health and Nutrition Examination Survey 2017–2020: Epidemiology, Clinical Correlates, and the Role of Diagnostic Scores. Metabolites 2022;12:1070.
- SHAHEEN A-A, BAGULEY E, SWAIN MG, TAM M, MA MM, SEBASTIANI G, et al. Diabetes and Obesity reduce FIB-4 accuracy in MASLD referral pathways. JHEP Reports 2026:101735.
- EDDOWES PJ, SASSO M, ALLISON M, TSOCHATZIS E, ANSTEE QM, SHERIDAN D, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717–30.
DOI: https://doi.org/10.2478/rjim-2026-0019 | Journal eISSN: 2501-062X (formerly 1220-4749) | Journal ISSN: 1220-4749
Language: English, Romanian
Submitted on: Jul 31, 2026
Published on: Sep 15, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Szymon Suwała, Paweł Rajewski, Roman Junik, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 License.